Rapid detection and quantitation of ganciclovir resistance in cytomegalovirus quasispecies

Journal of Medical Virology

Volumn 85, Issue 7, 2013, Pages 1250-1257

  Ruiz Carrascoso, Guillermo ^a   Romero Gómez, María Pilar ^a   Plaza, Diego ^a   Mingorance, Jesús ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiviral drug resistance; Ganciclovir; Human cytomegalovirus; Pyrosequencing; UL97 gene

Indexed keywords

CYCLOSPORIN; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ANTIVIRAL THERAPY; ARTICLE; CHILD; CYTOMEGALOVIRUS INFECTION; FEMALE; GENE MUTATION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOCOMPROMISED PATIENT; INFANT; MAINTENANCE THERAPY; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PYROSEQUENCING; UMBILICAL CORD BLOOD; VIRAL CLEARANCE; VIREMIA; VIRUS DETECTION; VIRUS LOAD; WILD TYPE;

ANTIVIRAL DRUG RESISTANCE; GANCICLOVIR; HUMAN CYTOMEGALOVIRUS; PYROSEQUENCING; UL97 GENE;

ANTIVIRAL AGENTS; CHILD, PRESCHOOL; CLINICAL LABORATORY TECHNIQUES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR SEQUENCE DATA; MUTATION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84878234787     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23570     Document Type: Article

References (37)

1. Baldanti F, Underwood MR, Talarico CL, Simoncini L, Sarasini A, Biron KK, Gerna G. 1998. The Cys607→Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob Agents Chemother 42:444-446.
2. Boivin G, Goyette N, Gilbert C, Covington E. 2005a. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 77:425-429.
3. Boivin G, Goyette N, Gilbert C, Humar A, Covington E. 2005b. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 7:166-170.
4. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 366:1175-1181.
5. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 in fluenza season in the United States. J Amer Med Assoc 295:891-894; 337.
6. Castor J, Cook L, Corey L, Jerome KR. 2007. Rapid detection directly from patient serum samples of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. J Clin Microbiol 45:2681-2683.
7. Chou S, Waldemer RH, Senters AE, Michels KS, Kemble GW, Miner RC, Drew WL. 2002. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 185:162-169.
8. Eckle T, Jahn G, Hamprecht K. 2004. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay. J Clin Virol 30:50-56.
9. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. 1999. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 190:177-182.
10. Erice A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 12:286-297.
11. Erice A, Gil-Roda C, Perez JL, Balfour HH, Jr., Sannerud KJ, Hanson MN, Boivin G, Chou S. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 175:1087-1092.
12. Gilbert C, Boivin G. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 49:873-883.
13. Gohring K, Mikeler E, Jahn G, Hamprecht K. 2006. Rapid simultaneous detection by real-time PCR of cytomegalovirus UL97 mutations in codons 460 and 520 conferring ganciclovir resistance. J Clin Microbiol 44:4541-4544.
14. Gohring K, Mikeler E, Jahn G, Rohde F, Hamprecht K. 2008. Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. Antivir Ther 13:461-466.
15. Gohring K, Feuchtinger T, Mikeler E, Lang P, Jahn G, Handgretinger R, Hamprecht K. 2009. Dynamics of the emergence of a human cytomegalovirus UL97 mutant strain conferring ganciclovir resistance in a pediatric stem-cell transplant 359 recipient. J Mol Diagn 11:364-368.
16. Gorzer I, Guelly C, Trajanoski S, Puchhammer-Stockl E. 2010. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J Virol 84:7195-7203.
17. Hamprecht K, Eckle T, Prix L, Faul C, Einsele H, Jahn G. 2003. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: Pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis 187:139-143.
18. Koetz AC, Delbruck R, Furtwangler A, Hufert FT, Neumann-Haefelin D, Kirste G, Meyer-Konig U. 2001. Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: A prospective, double-blind, placebo-controlled study. Transplantation 72:1325-1327.
19. Lackenby A, Democratis J, Siqueira MM, Zambon MC. 2008. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir Ther 13:809-820.
20. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP. 2007. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 45:439-447.
21. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. 2000. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645-649.
22. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. 2002. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 185:20-27.
23. Lurain NS, Weinberg A, Crumpacker CS, Chou S. 2001. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob Agents Chemother 45:2775-2780.
24. Lurain NS, Bhorade SM, Pursell KJ, Avery RK, Yeldandi VV, Isada CM, Robert ES, Kohn DJ, Arens MQ, Garrity ER, Taege AJ, Mullen MG, Todd KM, Bremer JW, Yen-Lieberman B. 2002. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 186:760-768.
25. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Berka J, Braverman MS, Chen YJ, Chen Z, Dewell SB, Du L, Fierro JM, Gomes XV, Godwin BC, He W, Helgesen S, Ho CH, Irzyk GP, Jando SC, Alenquer ML, Jarvie TP, Jirage KB, Kim JB, Knight JR, Lanza JR, Leamon JH, Lefkowitz SM, Lei M, Li J, Lohman KL, Lu H, Makhijani VB, McDade KE, McKenna MP, Myers EW, Nickerson E, Nobile JR, Plant R, Puc BP, Ronan MT, Roth GT, Sarkis GJ, Simons JF, Simpson JW, Srinivasan M, Tartaro KR, Tomasz A, Vogt KA, Volkmer GA, Wang SH, Wang Y, Weiner MP, Yu P, Begley RF, Rothberg JM. 2005. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376-380.
26. McGavin JK, Goa KL. 2001. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 61:1153-1183.
27. O'Meara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J. 2001. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol 39:464-473.
28. Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF. 2011. Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog 7:e1001344.
29. Ronaghi M, Karamohamed S, Pettersson B, Uhlen M, Nyren P. 1996. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 242:84-89.
30. Schindele B, Apelt L, Hofmann J, Nitsche A, Michel D, Voigt S, Mertens T, Ehlers B. 2010. Improved detection of mutated human cytomegalovirus UL97 by pyrosequencing. Antimicrob Agents Chemother 54:5234-5241.
31. Singh N. 2006. Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev Med Virol 16:281-287.
32. Snydman DR. 2006. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol 16:289-295.
33. Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. 1999. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 67:315-320.
34. Torres-Madriz G, Boucher HW. 2008. Immunocompromised hosts: Perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 47:702-711.
35. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. 2007. Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance. Genome Res 17:1195-1201.
36. Wolf DG, Smith IL, Lee DJ, Freeman WR, Flores-Aguilar M, Spector SA. 1995. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 95:257-263.
37. Yeo AC, Chan KP, Kumarasinghe G, Yap HK. 2005. Rapid detection of codon 460 mutations in the UL97 gene of ganciclovir-resistant cytomegalovirus clinical isolates by real-time PCR using molecular beacons. Mol Cell Probes 19:389-393.